The Treatment of Metastatic Prostatic Cancer With A Potent Luteinizing Hormone Releasing Hormone Analogue

Publisher Website
Google Scholar
Abstract
To assess the effect of the administration of a potent LHRH analog, (D-Leu-6)LHRH (1-9) nonapeptide ethylamide, 9 patients with previously untreated stage D2 prostatic cancer were treated with this agent for 3-8 mo. By 3 mo. of treatment all patients demonstrated a significant decrease in serum testosterone and a decreased peak serum luteinizing hormone and testosterone response to the acute administration of the analog, with no change in baseline serum luteinizing hormone or prolactin. These data suggest that this analog acts by decreasing the pituitary release of luteinizing hormone. No major adverse effects were noted with this treatment modality, and all patients were symptomatically improved and demonstrated a decrease or stabilization in tumor activity as measured by prostatic computerized tomography or ultrasound scan, prostatic acid phosphatase and bone scan. A representative case is presented. LHRH analogs may prove to be valuable new agents in the treatment of advanced prostatic cancer.